Rankings
▼
Calendar
IOVA
Iovance Biotherapeutics, Inc.
$2B
FY 2014 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$0
Gross Profit
-$9M
Operating Income
-$12M
Net Income
-$12M
EPS (Diluted)
$-0.48
Cash Flow
Operating Cash Flow
-$9M
Free Cash Flow
-$10M
Stock-Based Comp.
$4M
Balance Sheet
Total Assets
$47M
Total Liabilities
$2M
Stockholders' Equity
$45M
Cash & Equivalents
$45M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$0
$0
—
Gross Profit
-$9M
-$5M
-100.6%
Operating Income
-$12M
-$23M
+46.8%
Net Income
-$12M
-$25M
+52.6%
← FY 2013
All Quarters
FY 2015 →
IOVA FY 2014 Earnings — Iovance Biotherapeutics, Inc. Revenue & Financial Results | Market Cap Arena